NCT Number: NCT00544856
Effects of a Complex Cognitive Training in Mild Cognitive Impairment and Mild Alzheimer's Disease
A recent meta-analysis that included over 29.000 individuals found that the odds ratio (OR) of individuals with high brain reserve compared to low was 0.54 (p < 0.0001), a risk decrease of 46%. Among the factors that influence cognitive reserve, mentally stimulating activities was the most robust factor after controlling for education, age, occupation and other potential confounds. The brain reserve effect was sustained over a median longitudinal follow-up of 7 years. It would be interesting to detect whether a complex cognitive training could show similar effects on the cognitive abilities of patients with mild Alzheimer's disease (AD) and mild cognitive impairment (MCI) as it has been reported in previous studies based on mentally stimulating activities analysis.
The hypothesis is that a complex cognitive training alters the neural networks in both subject groups and this alteration is associated with improvement or stabilization of cognitive and non-cognitive function.
The investigator will perform a complex cognitive training program. Twenty patients with mild AD and twenty four patients with MCI will be recruited in this study. The patients will be randomised in control- and treatment groups.Additionally indirect effects on non-cognitive functions will be evaluated in caregivers of the patients.
The investigators expect that the cognitive and non-cognitive abilities will be changed during the cognitive training. The investigators also expect differences between treatment and control groups.
Looking for future studies?
Notify MeKey information
Conditions
Age range
55 year–95 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Not applicable
Who can participate
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Male or female patients aged ≥ 55 years, fulfilling criteria of the National Institute of Neurological and Communicative Disease and Stroke (NINCDS) and the Alzheimer's Disease and Related Disorders Association (ADRDA) for the diagnosis of clinically probable AD or Petersen's criteria of mild cognitive impairment (MCI)
- No evidence for other psychiatric axis I disorders according to DSM-IV criteria
- No uncontrolled arterial hypertension or diabetes mellitus
- No history of drug/alcohol abuse
- Cholinesterase inhibitors or Memantine must have been in a stabile doses at least 2 moths in AD subject group prior to the Baseline
- The patient is able to provide written informed consent to participate in the study. If, at investigator's discretion, a patient is considered not to be capable to give legal consent, then written consent must also be obtained from the patient's legally acceptable representative.
Exclusion criteria
- Evidence for other psychiatric axis I disorders according to DSM-IV criteria
- Uncontrolled arterial hypertension or diabetes mellitus
- History of drug/alcohol abuse
- No ability to participate and no willing to give informed consent and comply with the study restrictions
Treatment and study plan
Primary outcomes
-
cognition: MMSE, ADAS-cog.
Time frame: month 0, 6, 12
Secondary outcomes
-
quality of life
Time frame: month 0, 6, 12
Sponsors and collaborators
Lead sponsor
Ludwig-Maximilians - University of Munich
Other
Registry information
Important dates
- Study start
- 2007
- Primary completion
- 2008
- Study completion
- 2008
- First posted
- Oct 16, 2007
- Registry last updated
- Jan 29, 2009
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
A Study to Evaluate the Safety, Tolerability and Immunogenicity of Tau Targeted Vaccines in Participants With Early Alzheimer's Disease
NCT04445831
Alzheimer Disease, Alzheimer's Disease
Helsinki, Finland
View Trial DetailsSafety and Efficacy Study of Ladostigil in Mild to Moderate Probable Alzheimer's Disease
NCT01354691
Alzheimer Disease, Alzheimer's Disease
Graz, Austria
View Trial DetailsEffect of EGb761® on Brain Glucose Metabolism in Three Groups of Elderly Defined by Cognitive Functions
NCT00814346
Alzheimer Disease, Alzheimer's Disease
Issy-les-Moulineaux, France
View Trial DetailsFeasibility Trial of a Mediterranean Diet Pattern to Prevent Cognitive Decline
NCT02921672
Alzheimer Disease, Alzheimer's Disease
Kansas City, Kansas, United States
View Trial Details